Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy
Neovascular age-related macular degeneration (AMD) is a leading cause of irreversible visual loss in elderly populations. In recent years, pharmacological inhibition of vascular endothelial growth factor (VEGF), via intravitreal injection of ranibizumab (Lucentis) or bevacizumab (Avastin), has offer...
Main Authors: | Keane, Pearse A., Tufail, Adnan, Patel, Praveen J. |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228281/ |
Similar Items
-
Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration
by: Keane, Pearse A, et al.
Published: (2015) -
Modelling Cost Effectiveness in Neovascular Age-Related Macular Degeneration: The Impact of Using Contrast Sensitivity vs. Visual Acuity
by: Butt, Thomas, et al.
Published: (2014) -
Repeatability of retinal thickness and volume metrics in neovascular age-related macular degeneration using the topcon 3doct-1000
by: Tah, Vikas, et al.
Published: (2014) -
Intravitreal therapy in bilateral neovascular age-related macular degeneration
by: Barthelmes, D., et al.
Published: (2014) -
Missed Hospital Appointments of Patients Receiving Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Karampelas, Michael, et al.
Published: (2015)